Long-term Atazanavir Experience in a High HIV Caseload Primary Care Practice in Sydney, Australia (REfLecT)
研究概览
地位
条件
详细说明
This observational study will aim to determine long term atazanavir experience in HIV-1 infected patients in a primary care setting.
3. OBJECTIVES OF THE STUDY i. Primary objective Long-term (2 years or greater) atazanavir experience in HIV-1 infected patients in a primary care setting through retrospective data collection.
ii. Secondary objectives
- To illustrate long term therapeutic efficacy of atazanavir in ART naïve and experienced HIV-1 infected patients.
- To illustrate long term tolerability to atazanavir in ART naïve and experienced HIV-1 infected patients.
- To identify ART treatment history in ART naïve and experienced HIV-1 infected patients on ATV.
- To identify contraindicated therapy in ART naïve and experienced HIV-1 infected patients on ATV.
研究类型
注册 (实际的)
联系人和位置
学习地点
-
-
New South Wales
-
Sydney、New South Wales、澳大利亚、2010
- Holdsworth House Medical Practice
-
-
参与标准
资格标准
适合学习的年龄
- 孩子
- 成人
- 年长者
接受健康志愿者
有资格学习的性别
取样方法
研究人群
Cohort of HIV-1 positive patients attending Holdsworth House Medical Practice who have commenced ATV as a component of ART will be identified from review of current database.
Data will be collected retrospectively from patient electronic medical records for HIV-1 positive patients that have commenced ATV from year 2002 - 2008.
描述
Inclusion Criteria:
- HIV-1 positive
- Have commenced ATV between 2002-2008 (Baseline)
- Follow-up data (clinical and laboratory) available from baseline
Exclusion Criteria:
- Patients not commenced ATV between 2002-2008
- No follow-up data (clinical and laboratory) available from baseline
- Patient 'lost to follow-up' with < 2 years of follow-up data (Clinical and laboratory)
学习计划
研究是如何设计的?
设计细节
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Proportion of HIV-1 infected participants with atazanavir experience
大体时间:1 year
|
Proportion of patients who continue on atazanavir for 2 years or greater from baseline to termination/current.
|
1 year
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Proportion of HIV-1 infected participants with atazanavir experience
大体时间:1 year
|
1. Therapeutic efficacy of atazanavir
|
1 year
|
|
Proportion of HIV-1 infected participants with atazanavir experience
大体时间:1 year
|
Tolerability to atazanavir
|
1 year
|
|
Proportion of HIV-1 infected participants with atazanavir experience
大体时间:1 year
|
ART treatment history
|
1 year
|
|
Proportion of HIV-1 infected participants with atazanavir experience
大体时间:1 year
|
contraindicated therapy
|
1 year
|
合作者和调查者
调查人员
- 首席研究员:Mark Bloch, Dr.、Holdsworth House Medical Practice
研究记录日期
研究主要日期
学习开始
初级完成 (实际的)
研究完成 (实际的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (估计)
研究记录更新
最后更新发布 (估计)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.